Well, considering the manner in which the FDA listed the subject items (i.e., Actipatch therapy, ALLAY & RecoveryRx, as per their registration website, we should probably expect some spectacular news soon after the May 29th meeting. IMO, there is the possibility the Bayer/Dr. Scholl's deal will be included in a stunning four leafed PR clover. There probably won't be any significant PR material published by BIEL until soon after the upcoming meeting. That's my take!!
GO! BIEL!!
GLTA!!!